Table 1 Patient characteristics
Controls n = 38 | All patients N = 86 | TNFi n = 45 | RTX n = 31 | Anti-IL6R n = 5 | JAKi n = 5 | |
|---|---|---|---|---|---|---|
Demographic and clinical characteristics | ||||||
Sex (female) | 30 (79%) | 55 (64%) | 19 (42%) | 27 (87%) | 4 (80%) | 5 (100%) |
Age | 48 ± 14 | 56 ± 14* | 53 ± 13 | 61 ± 12 | 52 ± 22 | 56 ± 10 |
BMI | 24 ± 2.4 | 27 ± 6.1* | 26 ± 6.4 | 27 ± 5.4 | 26 ± 8.5 | 21 ± 1.6 |
Comorbidities | ||||||
Diabetes | 0 (0%) | 1 (1.2%) | 1 (2.2%) | 0 (0%) | 0 (0%) | 0 (0%) |
Arterial hypertension | 7 (18%) | 29 (34%) | 12 (27%) | 15 (48%) | 1 (20%) | 1 (20%) |
Current smokers | 4 (12%) | 12 (14%) | 5 (31%) | 5 (31%) | 1 (6.3%) | 1 (6.3%) |
Chronic lung disease | 4 (12.5%) | 2 (2.3%) | 0 (0%) | 2 (6.5%) | 0 (0%) | 0 (0%) |
Dyslipidemia | 11 (29%) | 26 (30%) | 13 (29%) | 13 (42%) | 0 (0%) | 0 (0%) |
Diagnosis | ||||||
RA | – | 50 (58%) | 15 (33%) | 27 (87%) | 3 (60%) | 5 (100%) |
SpA | – | 20 (23%) | 20 (45%) | 0 (0%) | 0 (0%) | 0 (0%) |
PsA | – | 10 (12%) | 10 (22%) | 0 (0%) | 0 (0%) | 0 (0%) |
CTD | – | 6 (7%) | 0 (0%) | 4 (13%) | 2 (40%) | 0 (0%) |
Serology findings | ||||||
RF+ | – | 45 (47%) | 13 (29%) | 25 (83%) | 2 (40%) | 5 (100%) |
ACPA+ | – | 47 (55%) | 14 (34%) | 25 (86%) | 3 (75%) | 5 (100%) |
HLA-B27+ | – | 14 (16%) | 14 (47%) | 0 (0%) | 0 (0%) | 0 (0%) |
ANA+ | – | 19 (22%) | 5 (12%) | 11 (38%) | 3 (40%) | 0 (0%) |
Treatment | ||||||
Methotrexate use | – | 63 (73%) | 23 (51%) | 16 (52%) | 2 (40%) | 4 (80%) |
Methotrexate dose (mg/week) | – | 16.5 ± 6.1 | 16 ± 6.5 | 17.5 ± 5.5 | 17.5 ± 3.5 | 13 ± 8 |
Prednisone use | – | 23 (27%) | 6 (13%) | 14 (45%) | 2 (40%) | 1 (20%) |
Prednisone dose (mg/day) | – | 3.14 ± 2.1 | 1 ± 1.1 | 3.6 ± 1.6 | 6.3 ± 1.7 | 2.5 ± 3.5 |
Time under b/tsDMARD | – | 12.1 ± 14.7 | 10.3 ± 7.4 | 17 ± 9.2 | 17 ± 13.2 | 16 ± 3.8 |